<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03578978</url>
  </required_header>
  <id_info>
    <org_study_id>NMRR-17-2491-38373</org_study_id>
    <nct_id>NCT03578978</nct_id>
  </id_info>
  <brief_title>A Panel of Biomarkers in Diagnosing Late-onset Neonatal Sepsis and Necrotizing Enterocolitis in Sibu Hospital</brief_title>
  <acronym>PISALONS</acronym>
  <official_title>A Panel of Biomarkers in Diagnosing Late-onset Neonatal Sepsis and Necrotizing Enterocolitis in Sibu Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinical Research Centre, Malaysia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinical Research Centre, Malaysia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a cross-sectional study to evaluate the utilities of a panel of biomarkers
      (Procalcitonin, Interleukin-6, Serum Amyloid A and Apolipoprotein C2) versus the gold
      standard blood culture result diagnosing late-onset neonatal sepsis (LONS) and/or necrotizing
      enterocolitis (NEC). Neonates who meet the initial screening criteria for suspected LONS or
      NEC will be recruited into the study. A group of 50 neonates who are clinically well,
      admitted to the nursery or general ward for reasons other than neonatal sepsis or NEC will
      also be recruited into the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The diagnosis of neonatal sepsis is challenging especially the very low birth weight infants
      as the signs and symptoms of sepsis are nonspecific and can be attributed to non-infected
      aetiologies including exacerbation of bronchopulmonary dysplasia, apnoea of prematurity and
      gastroesophageal reflux. Blood culture remains the gold standard for diagnosing septicaemia
      (either bacteremia or fungemia). However, its effectiveness in the population of preterm
      infants is compromised.Given the dire consequences of not treating the sepsis early,
      clinicians tend to have a low threshold for treatment. This leads to overuse of
      antimicrobials, promotion of antimicrobial resistance, exposure of infants to avoidable side
      effects from the antimicrobial treatment, prolonged hospitalisation and increased healthcare
      costs. Hence, there is a need for a clearly defined algorithm for diagnosing LONS and NEC.
      This study aims to examine the diagnostic utilities of a panel of sepsis biomarkers and
      explore if they can be incorporated into a diagnostic algorithm which hopefully, can be
      translated into clinical practice in the future.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic utilities of biomarkers of interest in diagnosing LONS</measure>
    <time_frame>Hour 0 to 72</time_frame>
    <description>Diagnostic utilities of each individual biomarker (procalcitonin, interleukin-6, serum amyloid A and apolipoprotein C2) or in combination in diagnosing LONS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic utilities of biomarkers of interest in diagnosing NEC</measure>
    <time_frame>Hour 0 to 72</time_frame>
    <description>Diagnostic utilities of each individual biomarker (procalcitonin, interleukin-6, serum amyloid A and apolipoprotein C2) or in combination in diagnosing LONS</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Neonatal SEPSIS</condition>
  <condition>Necrotizing Enterocolitis</condition>
  <arm_group>
    <arm_group_label>Neonates with suspected LONS and/or NEC</arm_group_label>
    <description>A group of 150 neonates with suspected LONS and/or NEC will be recruited. No intervention will be given to the subjects. Blood sampling will be obtained from subjects at 4 time points (Hour 0, 24, 48 and 72) for analysis of the sepsis biomarkers of interest.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy neonates</arm_group_label>
    <description>A group of 50 neonates who are clinically well, admitted to the NICU for reasons other than neonatal sepsis or NEC will be recruited into the study to explore the kinetics and concentrations of the panel of biomarkers in healthy subjects comparing to subjects with suspected LONS/NEC. No intervention will be given to the subjects. Blood sampling will be obtained from subjects at 4 time points (Hour 0, 24, 48 and 72) for analysis of the sepsis biomarkers of interest.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention will be given to study subjects. Only blood will be obtained from study subjects.</description>
    <arm_group_label>Healthy neonates</arm_group_label>
    <arm_group_label>Neonates with suspected LONS and/or NEC</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Neonates suspected of LONS and/or NEC admitted to the Neonatal Intensive Care Unit (NICU),
        Special Care Nursery (SCN) or Paediatric Medical 27 (PM27) wards in Sibu Hospital, Malaysia
        during the period of 1 July 2018 and 31 May 2020 will be screened for their eligibility.
        Apart from that, neonates admitted to Sibu Hospital for reasons other than neonatal sepsis
        or NEC will also be recruited into the study during the period of 1 June 2018 and 31 May
        2020.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Neonates with suspected LONS/NEC

        Inclusion Criteria:

          -  Infants with signs and symptoms suggestive of sepsis and/or NEC and requiring full
             sepsis screening and start of intravenous antibiotic(s), or a change of antibiotics
             (if already on)

          -  Infants with postnatal age greater than 72 hours and less than 28 days of life, of all
             gestation

          -  Parents of potential neonates who are willing to give written informed consent

        Healthy subjects

        Inclusion Criteria:

          -  Clinically well infants admitted to Sibu Hospital for reasons other than neonatal
             sepsis or NEC

          -  Infants with postnatal age greater than 72 hours and less than 28 days of life, of all
             gestation

        Exclusion Criteria:

          -  Infants who have lethal or life-threatening congenital abnormalities

          -  Infants who have chromosomal abnormalities

          -  Infants who have hypoxic ischemic encephalopathy

          -  Infants who are on steroid treatment

          -  Infants who received blood transfusions

          -  Post-operative infants
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>30 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shirin Hui Tan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research Centre, Sarawak General Hospital, Malaysia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shirin Hui Tan</last_name>
    <phone>+6082-276820</phone>
    <email>shirin_hui88@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sarawak General Hospital</name>
      <address>
        <city>Kuching</city>
        <state>Sarawak</state>
        <zip>93586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shirin H Tan</last_name>
      <phone>6082276820</phone>
      <email>shirin_hui88@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Ann Cheng Wong</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lee Gaik Chan</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Janet Lin Yee Hii</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Debbie Diewo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kim Lai Ng</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Janet Huey Jing Liew</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hui Ling Sim</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sibu Hospital</name>
      <address>
        <city>Sibu</city>
        <state>Sarawak</state>
        <zip>96000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shirin Hui Tan</last_name>
    </contact>
    <investigator>
      <last_name>See Chang Wong</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Teck Hock Toh</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chae Hee Chieng</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Phaik Ngan Lee</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yi-Pinn Tai</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wei Nin Kong</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Justina Sie Wei Lau</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hanizah Amran</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 25, 2018</study_first_submitted>
  <study_first_submitted_qc>June 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2018</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Neonatal Sepsis</mesh_term>
    <mesh_term>Enterocolitis</mesh_term>
    <mesh_term>Enterocolitis, Necrotizing</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

